RESEARCH ARTICLE

Targeting papain-like protease for broad-spectrum coronavirus inhibition

  • Shuofeng Yuan , 1,2 ,
  • Xiaopan Gao 3 ,
  • Kaiming Tang 2 ,
  • Jian-Piao Cai 2 ,
  • Menglong Hu 4 ,
  • Peng Luo 2 ,
  • Lei Wen 2 ,
  • Zi-Wei Ye 2 ,
  • Cuiting Luo 2 ,
  • Jessica Oi-Ling Tsang 2 ,
  • Chris Chun-Yiu Chan 2 ,
  • Yaoqiang Huang 2 ,
  • Jianli Cao 2 ,
  • Ronghui Liang 2 ,
  • Zhenzhi Qin 2 ,
  • Bo Qin 3 ,
  • Feifei Yin 6,7,8 ,
  • Hin Chu 1,2 ,
  • Dong-Yan Jin 4,9 ,
  • Ren Sun 4,5 ,
  • Jasper Fuk-Woo Chan , 1,2,7,8,9,10 ,
  • Sheng Cui , 3 ,
  • Kwok-Yung Yuen , 1,2,7,8,9,10
Expand
  • 1. State Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
  • 2. Department of Microbiology, Li Ka Shing, Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
  • 3. NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
  • 4. School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
  • 5. Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
  • 6. Key Laboratory of Tropical Translational Medicine of Ministry of Education, Hainan Medical University, Haikou 571199, China
  • 7. Academician Workstation of Hainan Province, Hainan Medical University, Haikou 571199, China
  • 8. Hainan Medical University-The University of Hong Kong Joint Laboratory of Tropical Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
  • 9. Guangzhou Laboratory, Guangzhou 510320, China
  • 10. Department of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen 518053, China

Received date: 01 Sep 2021

Accepted date: 17 Feb 2022

Published date: 15 Dec 2022

Copyright

2022 The Author(s) 2022

Abstract

The emergence of SARS-CoV-2 variants of concern and repeated outbreaks of coronavirus epidemics in the past two decades emphasize the need for next-generation pan-coronaviral therapeutics. Drugging the multi-functional papain-like protease (PLpro) domain of the viral nsp3 holds promise. However, none of the known coronavirus PLpro inhibitors has been shown to be in vivo active. Herein, we screened a structurally diverse library of 50,080 compounds for potential coronavirus PLpro inhibitors and identified a noncovalent lead inhibitor F0213 that has broad-spectrum anti-coronaviral activity, including against the Sarbecoviruses (SARS-CoV-1 and SARS-CoV-2), Merbecovirus (MERS-CoV), as well as the Alphacoronavirus (hCoV-229E and hCoV-OC43). Importantly, F0213 confers protection in both SARS-CoV-2-infected hamsters and MERS-CoV-infected human DPP4-knockin mice. F0213 possesses a dual therapeutic functionality that suppresses coronavirus replication via blocking viral polyprotein cleavage, as well as promoting antiviral immunity by antagonizing the PLpro deubiquitinase activity. Despite the significant difference of substrate recognition, mode of inhibition studies suggest that F0213 is a competitive inhibitor against SARS2-PLpro via binding with the 157K amino acid residue, whereas an allosteric inhibitor of MERS-PLpro interacting with its 271E position. Our proof-ofconcept findings demonstrated that PLpro is a valid target for the development of broad-spectrum anti-coronavirus agents. The orally administered F0213 may serve as a promising lead compound for combating the ongoing COVID-19 pandemic and future coronavirus outbreaks.

Cite this article

Shuofeng Yuan , Xiaopan Gao , Kaiming Tang , Jian-Piao Cai , Menglong Hu , Peng Luo , Lei Wen , Zi-Wei Ye , Cuiting Luo , Jessica Oi-Ling Tsang , Chris Chun-Yiu Chan , Yaoqiang Huang , Jianli Cao , Ronghui Liang , Zhenzhi Qin , Bo Qin , Feifei Yin , Hin Chu , Dong-Yan Jin , Ren Sun , Jasper Fuk-Woo Chan , Sheng Cui , Kwok-Yung Yuen . Targeting papain-like protease for broad-spectrum coronavirus inhibition[J]. Protein & Cell, 2022 , 13(12) : 940 -953 . DOI: 10.1007/s13238-022-00909-3

1
Báez-SantosYM, Barraza SJ, WilsonMW, AgiusMP, Mielech AM, DavisNM, BakerSC, LarsenSD, MesecarAD (2014) X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases. J Med Chem 57(6):2393–2412

DOI

2
Baez-SantosYM, Mielech AM, DengX, BakerS, Mesecar AD (2014) Catalytic function and substrate specificity of the papainlike protease domain of nsp3 from the Middle East respiratory syndrome coronavirus. J Virol 88(21):12511–12527

DOI

3
Baez-SantosYM, St John SE, MesecarAD (2015) The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res 115:21–38

DOI

4
BarrettoN, Jukneliene D, RatiaK, ChenZ, Mesecar AD, BakerSC (2005) The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. J Virol 79 (24):15189–15198

DOI

5
Blanco-MeloD, Nilsson-Payant BE, LiuWC, UhlS, Hoagland D, MøllerR, JordanTX, OishiK, PanisM, Sachs D et al (2020) Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181(5):1036–1045.e9

DOI

6
ChanJF, LauSK, ToKK, ChengVC, WooPC, Yuen KY (2015) Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev 28(2):465–522

DOI

7
ChanJF, ZhangAJ, YuanS, Poon VK, ChanCC, LeeAC, ChanWM, FanZ, TsoiHW, WenL et al (2020) Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin Infect Dis 71 (9):2428–2446

DOI

8
ChuH, ShuaiH, HouY, ZhangX, WenL, HuangX, HuB, YangD, WangY, Yoon C et al (2021) Targeting highly pathogenic coronavirus-induced apoptosis reduces viral pathogenesis and disease severity. Sci Adv 7(25):eabf8577

DOI

9
ClasmanJR, Everett RK, SrinivasanK, MesecarAD (2020) Decoupling deISGylating and deubiquitinating activities of the MERS virus papain-like protease. Antiviral Res 174:104661

DOI

10
FuZ, HuangB, TangJ, Liu S, LiuM, YeY, LiuZ, XiongY, Zhu W, CaoD et al (2021) The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery. Nat Commun 12(1):488

DOI

11
GaoX, MuZ, YuX, QinB, WojdylaJ, Wang M, CuiS (2018) Structural insight into conformational changes induced by ATP binding in a type III secretion-associated ATPase from Shigella flexneri. Front Microbiol 9:1468

DOI

12
GaoX, QinB, ChenP, Zhu K, HouP, WojdylaJA, WangM, CuiS (2021) Crystal structure of SARS-CoV-2 papain-like protease. Acta Pharm Sin B 11(1):237–245

DOI

13
GiannakopoulosNV, Arutyunova E, LaiC, LenschowDJ, HaasAL, VirginHW (2009) ISG15 Arg151 and the ISG15-conjugating enzyme UbE1L are important for innate immune control of sindbis virus. J Virol 83(4):1602–1610

DOI

14
GuZ, EilsR, SchlesnerM (2016) Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32(18):2847–2849

DOI

15
İnandıklıoğluN, AkkocT (2020) Immune responses to SARS-CoV, MERS-CoV and SARS-CoV-2. Adv Exp Med Biol 1288:5–12

DOI

16
KimS, ChenJ, ChengT, Gindulyte A, HeJ, HeS, LiQ, ShoemakerBA, Thiessen PA, YuB et al (2021) PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res 49(D1):D1388–D1395

DOI

17
KlemmT, EbertG, CallejaDJ, Allison CC, RichardsonLW, BernardiniJP, LuBG, KuchelNW, Grohmann C, ShibataY et al (2020) Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2. EMBO J 39(18):e106275

DOI

18
KumarS, Stecher G, LiM, KnyazC, TamuraK (2018) MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol 35(6):1547–1549

DOI

19
LiK, Wohlford-Lenane CL, ChannappanavarR, ParkJE, Earnest JT, BairTB, BatesAM, Brogden KA, FlahertyHA, GallagherT et al (2017) Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proc Natl Acad Sci U S A 114(15):E3119–E3128

DOI

20
OsipiukJ, AziziSA, DvorkinS, Endres M, JedrzejczakR, JonesKA, KangS, KathayatRS, Kim Y, LisnyakVG et al (2021) Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. Nat Commun 12(1):743

DOI

21
RatiaK, PeganS, TakayamaJ, Sleeman K, CoughlinM, BalijiS, Chaudhuri R, FuW, PrabhakarBS, Johnson ME et al (2008) A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A 105(42):16119–16124

DOI

22
ShanH, LiuJ, ShenJ, Dai J, XuG, LuK, HanC, WangY, Xu X, TongY et al (2021) Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2. Cell Chem Biol 28(6):855–865.e9

DOI

23
SharmaA, GarciaG Jr, WangY, Plummer JT, MorizonoK, ArumugaswamiV, Svendsen CN (2020) Human iPSC-derived cardiomyocytes are susceptible to SARS-CoV-2 infection. Cell Rep Med 1(4):100052

DOI

24
ShinD, Mukherjee R, GreweD, BojkovaD, BaekK, BhattacharyaA, SchulzL, WideraM, MehdipourAR, Tascher G et al (2020) Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 587(7835):657–662

DOI

25
SieversF, Higgins DG (2018) Clustal Omega for making accurate alignments of many protein sequences. Protein Sci 27(1):135–145

DOI

26
WolffG, Limpens RWAL, Zevenhoven-DobbeJC, LaugksU, ZhengS, de JongAWM, Koning RI, AgardDA, GrünewaldK, KosterAJ et al (2020) A molecular pore spans the double membrane of the coronavirus replication organelle. Science 369(6509):1395–1398

DOI

27
WongLR, YeZW, LuiPY, Zheng X, YuanS, ZhuL, FungSY, YuenKS, Siu KL, YeungML et al (2020) Middle east respiratory syndrome coronavirus ORF8b accessory protein suppresses type I IFN expression by impeding HSP70-dependent activation of IRF3 kinase IKKϵ. J Immunol 205(6):1564–1579

DOI

28
YuGC, LamTT, ZhuH, GuanY (2018) Two methods for mapping and visualizing associated data on phylogeny using Ggtree. Mol Biol Evol 35(12):3041–3043

DOI

29
YuanS, ChuH, ZhangK, Ye J, SinghK, KaoRY, ChowBK, ZhouJ, Zheng BJ (2016) A novel small-molecule compound disrupts influenza A virus PB2 cap-binding and inhibits viral replication. J Antimicrob Chemoth 71(9):2489–2497

DOI

30
YuanS, WangR, ChanJF, Zhang AJ, ChengT, ChikKK, YeZW, WangS, Lee AC, JinL et al (2020) Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. Nat Microbiol 5(11):1439–1448

DOI

31
YuanS, ChuH, HuangJ, Zhao X, YeZW, LaiPM, WenL, CaiJP, Mo Y, CaoJ et al (2020) Viruses harness YxxO motif to interact with host AP2M1 for replication: a vulnerable broad-spectrum antiviral target. Sci Adv 6(35):eaba7910

DOI

32
YuanS, YinX, MengX, Chan JF, YeZW, RivaL, PacheL, ChanCC, Lai PM, ChanCC et al (2021) Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. Nature 593(7859):418–423

DOI

33
ZhaoY, DuX, DuanY, Pan X, SunY, YouT, HanL, JinZ, ShangW, YuJ et al (2021) High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors. Protein Cell 12(11):877–888

DOI

Outlines

/